US 12,115,341 B2
Drug delivery device
Lawrence Ring, Valencia, CA (US); Dhairya Mehta, South San Francisco, CA (US); Stephanie Toy, Moorpark, CA (US); Ferry Tamtoro, Newbury Park, CA (US); Alexander Stuart Cairns, Santa Monica, CA (US); and Scott R. Gibson, Granada Hills, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 14/443,847
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Nov. 20, 2013, PCT No. PCT/US2013/070929
§ 371(c)(1), (2) Date May 19, 2015,
PCT Pub. No. WO2014/081780, PCT Pub. Date May 30, 2014.
Claims priority of provisional application 61/774,567, filed on Mar. 7, 2013.
Claims priority of provisional application 61/729,303, filed on Nov. 21, 2012.
Prior Publication US 2015/0290390 A1, Oct. 15, 2015
Int. Cl. A61M 5/142 (2006.01); A61K 9/00 (2006.01); A61K 38/19 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61M 5/14 (2006.01); A61M 5/158 (2006.01); A61M 5/20 (2006.01); A61M 5/30 (2006.01); A61M 5/31 (2006.01); A61M 5/32 (2006.01); A61M 5/42 (2006.01); A61M 25/00 (2006.01); A61M 25/02 (2006.01); C07K 14/535 (2006.01); C12N 9/64 (2006.01)
CPC A61M 5/14248 (2013.01) [A61K 9/0019 (2013.01); A61K 38/193 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61M 5/14 (2013.01); A61M 5/14216 (2013.01); A61M 5/158 (2013.01); A61M 5/20 (2013.01); A61M 5/3134 (2013.01); A61M 5/3286 (2013.01); A61M 5/3287 (2013.01); A61M 5/3291 (2013.01); A61M 5/422 (2013.01); A61M 25/0015 (2013.01); A61M 25/0068 (2013.01); A61M 25/007 (2013.01); A61M 25/02 (2013.01); C07K 14/535 (2013.01); C12N 9/6424 (2013.01); A61M 2005/1401 (2013.01); A61M 2005/1585 (2013.01); A61M 2005/3022 (2013.01); A61M 2005/3289 (2013.01); A61M 2025/0073 (2013.01); A61M 2202/0007 (2013.01)] 44 Claims
OG exemplary drawing
 
1. A wearable drug delivery device comprising:
a housing having an opening;
a blunt cannula moveable relative to the housing and having a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula, the wall having at least a first tapered region at the first end to define an opening in fluid communication with the axial passage, and at least one side port formed in the wall at the first end of the blunt cannula to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula, wherein no side ports are formed in the wall of the blunt cannula at the second end of the blunt cannula;
a reservoir for storing a drug prior to operation of the wearable drug delivery device and configured to be in fluid communication with the second end of the blunt cannula at least during drug delivery;
a needle or connector configured to connect the blunt cannula in fluid communication with the reservoir;
a hub disposed at or coupled with the second end of the blunt cannula, the hub at least partially surrounding at least a portion of the needle or connector; and
wherein the blunt cannula is initially retracted within the housing and subsequently the first end of the blunt cannula is deployed through the opening in the housing in an operative state, wherein the second end of the blunt cannula is disposed within the housing in the operative state.
 
27. A wearable drug delivery device comprising:
a housing having an outer surface attachable to a patient, an opening being formed in the outer surface of the housing;
a rigid needle moveable relative to the housing and having a cylindrical wall that defines an axial passage between a first end and a second end of the rigid needle, the wall having an opening at the first end in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the rigid needle; and
a reservoir configured to be in fluid communication with the second end of the rigid needle at least during drug delivery,
wherein the first end includes a pattern of openings disposed about the opening in the first end, and at least one external recessed region recessed toward the axial passage relative to adjoining surface regions, the at least one external recessed region being distal from the pattern of openings toward the second end of the rigid needle, and
wherein the rigid needle is initially retracted within the housing and subsequently deployed through the opening in the housing to define an operative state.
 
34. A wearable drug delivery device comprising:
a housing having an outer surface attachable to a patient, an opening being formed in the outer surface of the housing;
a rigid needle moveable relative to the housing and having a cylindrical wall that defines an axial passage between a first end and a second end of the rigid needle, the wall having an opening at the first end in fluid communication with the axial passage;
a vibration generator coupled to the rigid needle and configured to move, during drug delivery, the first end of the rigid needle away from an occluding structure to resist interruption of fluid flow through the axial passage and out of the first end of the rigid needle; and
a reservoir configured to be in fluid communication with the second end of the rigid needle at least during drug delivery,
wherein the rigid needle is initially retracted within the housing and subsequently automatically deployed through the opening in the housing in an operative state.
 
39. A wearable drug delivery device comprising:
a housing having an outer surface and an opening formed in the outer surface;
a reservoir for storing a drug prior to operation of the wearable drug delivery device;
a cannula having a cylindrical wall that defines an axial passage between a first end and a second end of the cannula, an opening being formed in the first end of the cannula, the first end of the cannula being initially retracted within the housing and configured to be subsequently deployed through the opening in the outer surface of the housing for introduction into skin of a patient during operation of the drug delivery device, the second end of the cannula being disposed within the housing during operation of the drug delivery device, the cannula configured to be operably connected in fluid communication with the reservoir to deliver the drug to the patient during operation of the drug delivery device;
an introducer needle disposed in the cannula and adapted to protrude outwardly from the opening in the first end of the cannula for introducing the cannula into the skin of the patient and subsequently retract into the opening in the first end of the cannula prior to delivery of the drug to the patient;
an outer surface of the cannula configured to frictionally engage and drag the skin of the patient upon introduction of the cannula into the skin of the patient such that introduction of the cannula into the skin of the patient causes tenting in the skin of the patient; and
at least one side port formed in the wall of the cannula at the first end of the cannula to resist interruption of fluid flow through the axial passage and out of the first end of the cannula, and wherein no side ports are formed in the wall of the cannula at the second end of the cannula.